The Cohort Consortium Vitamin D Pooling Project of Rarer Cancers failed to find a reduced risk of cancer incidence associated with higher levels (>75 nmol/L) of serum 25-hydroxyvitamin D (25(OH)D) for 7 types of cancer: endometrial, esophageal, gastric, kidney, ovarian, and pancreatic, as well as non-Hodgkin's lymphoma (1). These results are in stark contrast to those of many ecologic studies, which almost invariably found strong inverse correlations for ultraviolet B doses for these cancers even after accounting for confounding factors (2-7). In addition, a cohort study found significant inverse correlations with an index of serum 25(OH)D level for 5 types of cancer, including pancreatic and esophageal, and nonsignificant inverse correlations for 6 types of cancer, including gastric, kidney, and non-Hodgkin's lymphoma (8) (also refer to Bao et al. (9)).
cers in sunnier countries such as Australia, Singapore, and Spain (4, 13) supports the long-term perspective.
Regarding the representativeness of a single serum 25(OH)D level measurement, 2 factors give rise to changes in serum 25(OH)D levels. One is concern about skin cancer, probably leading to lower serum 25(OH)D levels (14) . The other is increased vitamin D supplementation due to widespread publicity in the past decade about the health benefits of vitamin D. Two studies found that serum 25(OH)D levels can vary significantly over time (15, 16) . A randomized, controlled trial of vitamin D and calcium supplementation found a 35% reduction in all-cancer incidence between the ends of the first and fourth years, which was attributed to 1,100 IU/day of vitamin D (17) . Thus, recent serum 25(OH)D levels can significantly affect cancer incidence rates.
